astragaloside a has been researched along with Disease Exacerbation in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, S; Liu, J; Liu, M; Song, L; Sun, Z; Wang, X | 1 |
| Jia, L; Lv, D; Wang, Z; Zhang, S; Zhou, B | 1 |
| Cui, J; Cui, WQ; Dong, JC; Gong, WY; Hu, LL; Liu, BJ; Qiu, J; Wei, Y; Xu, F | 1 |
| Du, M; Gao, Y; He, Y; Liu, H; Wang, H; Wang, Z; Wu, X | 1 |
| Le, V; Lin, S; Liu, J; Que, Z; Tian, J; Zhang, A; Zhang, L; Zheng, Y | 1 |
5 other study(ies) available for astragaloside a and Disease Exacerbation
| Article | Year |
|---|---|
Astragaloside IV antagonizes M2 phenotype macrophage polarization-evoked ovarian cancer cell malignant progression by suppressing the HMGB1-TLR4 axis.
Topics: Cell Movement; Cell Polarity; Disease Progression; Female; HMGB1 Protein; Humans; Macrophage Activation; Macrophages; Ovarian Neoplasms; Phenotype; Saponins; Signal Transduction; THP-1 Cells; Toll-Like Receptor 4; Triterpenes; Tumor Cells, Cultured; Tumor Microenvironment | 2021 |
Astragaloside IV Inhibits the Progression of Non-Small Cell Lung Cancer Through the Akt/GSK-3β/β-Catenin Pathway.
Topics: Apoptosis; beta Catenin; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disease Progression; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Saponins; Signal Transduction; Triterpenes | 2019 |
Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling.
Topics: A549 Cells; AMP-Activated Protein Kinase Kinases; Cell Polarity; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Interleukin-13; Lung Neoplasms; Macrophages; Neoplasm Metastasis; Protein Kinases; Saponins; Signal Transduction; Triterpenes; Vesicular Transport Proteins | 2018 |
Astragaloside IV attenuates experimental autoimmune encephalomyelitis of mice by counteracting oxidative stress at multiple levels.
Topics: Animals; Antioxidants; Apoptosis Regulatory Proteins; CD11b Antigen; Cell Line; Cytokines; Demyelinating Diseases; Disease Models, Animal; Disease Progression; Drugs, Chinese Herbal; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Inflammation; Mice; Multiple Sclerosis; Nerve Tissue Proteins; Nitric Oxide Synthase Type II; Nuclear Receptor Subfamily 1, Group F, Member 3; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Saponins; T-Box Domain Proteins; Th1 Cells; Th17 Cells; Triterpenes | 2013 |
Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Coculture Techniques; Disease Progression; Drug Screening Assays, Antitumor; Female; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, Inbred C57BL; Neoplasm Transplantation; Paclitaxel; Saponins; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Triterpenes; Tryptophan; Tumor Burden; Tumor Escape | 2014 |